Q-omics provides the consensus-scored SLC51B profile across patient tissues and cancer cell-line models. SLC51B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC51B is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, SLC51B RNA expression shows 17,445 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, COAD, and LSCC as cancer lineages where SLC51B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC51B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC51B survival associations across molecular data types. SLC51B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC51B RNA expression–survival associations across cancer types. High SLC51B expression shows unfavorable associations in UVM, ESCA and BLCA, but favorable associations in KIRC, LUAD and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC51B RNA expression.
This table summarizes SLC51B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC51B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC51B shows lower tumor expression in COAD, BLCA, LUSC, LUAD and UCEC and higher tumor expression in LIHC. The COAD box plot shows higher SLC51B RNA expression in normal versus tumor tissue (log2 FC = −4.464, t-test p < 0.001).
This table shows molecular features associated with SLC51B in patient tissues and cancer cell lines. In patient samples, SLC51B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC51B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
